<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00641979</url>
  </required_header>
  <id_info>
    <org_study_id>SD-005-0698</org_study_id>
    <secondary_id>D5360C00698</secondary_id>
    <nct_id>NCT00641979</nct_id>
  </id_info>
  <brief_title>New Nasal Applicator / New Formulation - User Study</brief_title>
  <official_title>A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Functionality of a New Nasal Device With Reformulated Rhinocort Aqua (Budesonide) Versus the Current Product and Versus Placebo in Subjects With Seasonal Allergic Rhinitis (SAR).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of once daily dosing with Rhinocort Aqua
      (new formulation) against Rhinocort Aqua (current formulation) and placebo in reliving the
      symptoms of seasonal allergic rhinitis (SAR).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">August 2002</completion_date>
  <primary_completion_date type="Actual">August 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Total Nasal Symptom scores (Rhinorrhea, Congestion, Itching &amp; Sneezing)</measure>
    <time_frame>2 weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Durability of device</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessment via adverse events and clinical measurements</measure>
    <time_frame>2 weekly</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rhinocort</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide</intervention_name>
    <description>Current product</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rhinocort AQUA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Budesonide</intervention_name>
    <description>New type device</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Rhinocort Aqua</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In the opinion of the investigator, is a candidate for treatment with nasal steroids
             based on a history of either a) inadequate control of symptoms with antihistamines,
             decongestants and/or immunotherapy, or b) prior successful treatment with nasal
             steroids.

          -  A documented history of at least one year of seasonal allergic rhinitis.

          -  A positive response to a skin prick test for grass allergens that must be present in
             the subject's environment throughout the study.

        Exclusion Criteria:

          -  Primary or secondary adrenal insufficiency

          -  Nasal candidiasis, rhinitis medicamentosa, acute or chronic sinusitis, influenza,
             upper respiratory tract infection or structural abnormalities of the nose (e.g.,
             septal deviation, nasal polyps) symptomatic enough to cause significant nasal
             obstruction as judged by the investigator.

          -  A diagnosis of asthma requiring treatment as specified in the protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaile Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Allergy &amp; Asthma Consultant, NJ, USA.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bertil Andersson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2008</study_first_posted>
  <last_update_submitted>January 21, 2011</last_update_submitted>
  <last_update_submitted_qc>January 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2011</last_update_posted>
  <keyword>Allergic rhinitis</keyword>
  <keyword>Nasal symptoms</keyword>
  <keyword>Congestion</keyword>
  <keyword>Rhinorrhea</keyword>
  <keyword>Sneeze</keyword>
  <keyword>budesonide</keyword>
  <keyword>Rhinocort AQUA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

